The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National …
HD Bear, S Anderson, A Brown, R Smith… - Journal of clinical …, 2003 - ascopubs.org
Purpose: The National Surgical Adjuvant Breast and Bowel Project Protocol B-27 was
designed to determine the effect of adding docetaxel after four cycles of preoperative …
designed to determine the effect of adding docetaxel after four cycles of preoperative …
[HTML][HTML] Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta …
Background Guidelines recommend primary prophylaxis (PP) with granulocyte-colony-
stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of …
stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of …
Chemotherapy for metastatic breast cancer–report of a European expert panel
J Crown, V Diéras, M Kaufmann… - The Lancet …, 2002 - thelancet.com
The anthracyclines doxorubicin and epirubicin, and the taxanes paclitaxel and docetaxel,
are effective chemotherapeutic agents for the first-line and second-line treatment of …
are effective chemotherapeutic agents for the first-line and second-line treatment of …
Docetaxel administered on a weekly basis for metastatic breast cancer
HJ Burstein, J Manola, J Younger, LM Parker… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel in women with
metastatic breast cancer. PATIENTS AND METHODS: Twenty-nine women were enrolled …
metastatic breast cancer. PATIENTS AND METHODS: Twenty-nine women were enrolled …
Therapeutic options for metastatic breast cancer
PG Morris, HL McArthur, CA Hudis - Expert opinion on …, 2009 - Taylor & Francis
Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic
advances. Recently there has been progress extending the range of available cytotoxic …
advances. Recently there has been progress extending the range of available cytotoxic …
[HTML][HTML] Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage …
M Schmidt, D Rüttinger, M Sebastian, CA Hanusch… - Annals of oncology, 2012 - Elsevier
Background Targeted therapy options in HER2-negative breast cancer are limited. This
open-label, multicenter phase IB dose-escalation trial was conducted to determine safety …
open-label, multicenter phase IB dose-escalation trial was conducted to determine safety …
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions
S Goble, HD Bear - Surgical Clinics, 2003 - surgical.theclinics.com
Over the past 3 decades, the importance of systemic chemotherapy for improving the
survival of women with breast cancer has increasingly been recognized. Adjuvant systemic …
survival of women with breast cancer has increasingly been recognized. Adjuvant systemic …
Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative …
JA Wils, JM Bliss, M Marty, G Coombes… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To assess whether the addition of epirubicin (EPI) therapy to prolonged
treatment with tamoxifen (TAM) improves relapse-free and overall survival in …
treatment with tamoxifen (TAM) improves relapse-free and overall survival in …
Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With …
E Salminen, M Bergman, S Huhtala… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: Patients with metastatic breast cancer, especially those with progression after
several prior chemotherapy treatments, need efficient chemotherapy. This study investigates …
several prior chemotherapy treatments, need efficient chemotherapy. This study investigates …
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer
N Karachaliou, N Ziras, K Syrigos, K Tryfonidis… - Cancer chemotherapy …, 2012 - Springer
Objective To evaluate the efficacy and safety of docetaxel plus capecitabine (DC)
combination as salvage treatment in anthracycline-and taxane-pretreated patients with …
combination as salvage treatment in anthracycline-and taxane-pretreated patients with …